Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
Boland
A
A
Liverpool Reviews and Implementation Group, New Medical School, Liverpool, UK.
Dundar
Y
Y
Bagust
A
A
Haycox
A
A
Hill
R
R
Mujica Mota
R
R
Walley
T
T
Dickson
R
R
D003362:Cost-Benefit Analysis; D004341:Drug Evaluation; D004638:Emergency Treatment / Q000191:economics; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000145:classification / Q000191:economics* / Q000627:therapeutic use*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000191:economics; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013300:Streptokinase / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000077785:Tenecteplase; D015912:Thrombolytic Therapy / Q000191:economics*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase